检索
AI 对话
AI 辅写
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer

Vijay Patil,Vanita Noronha,Amit Joshi,Anuradha Chougule,Sadhana Kannan,Atanu Bhattacharjee,Supriya Goud,Sucheta More,Arun Chandrasekharan,Nandini Menon,Sujay Srinivas,Dilip Harindran Vallathol,Hollis Dsouza,Swaratika Majumdar,Sudeep Das, Abhinav Zawar,Satvik Khaddar,Amit Kumar, Gunjesh Singh, Kanteti Aditya Pavan Kumar,Rahul Ravind,Vaishakhi Trivedi,Vichitra Behel,Abhishek Mahajan,Amit Janu,Nilendu Purandare,Kumar Prabhash

EClinicalMedicine（2019）

引用 6|浏览7
暂无评分
摘要
This study suggests that PLDG is an alternative to the standard gemcitabine schedule in squamous NSCLC, and either of these can be selected subject to patient convenience.
更多
查看译文
关键词
Gemcitabine,Low dose,Prolonged infusion,Squamous cell cancer,NSCLC
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要